Latest KFF Health News Stories
Podcast: KHN’s ‘What The Health?’ The State Of The (Health) Union
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Alice Ollstein of Talking Points Memo and Julie Appleby and Sarah Jane Tribble of Kaiser Health News discuss President Donald Trump’s promises to reduce drug prices in his first State of the Union Address. The panelists also discuss the departure of the director of the Centers for Disease Control and Prevention after conflict-of-interest reports and the efforts by some states to flout the Affordable Care Act.
Expert Advice For The Corporate Titans Taking On Health Care
Amazon, Berkshire Hathaway and JPMorgan Chase & Co. are partnering up to address employee health care costs and improve satisfaction. Can they deliver? And would repackaging health insurance involve drones?
States Face Costly Conundrum: How To Treat Inmates With Hepatitis C
Although the potentially fatal disease is common among the incarcerated, treatment with the latest hepatitis drugs isn’t.
Podcast: What The Health? Our First Live Show: What The Health Will Happen In 2018?
In this episode of “What The Health?” — taped before a live audience — panelists discuss the potential federal government shutdown and what may be in store for health in 2018. They are joined by former Medicare and Medicaid head Tom Scully.
Fallout From ‘Nuclear Button’ Tweets: Sales Of Anti-Radiation Drug Skyrocket
Orders for potassium iodide reportedly jumped after a Jan. 2 war of words between Trump and North Korea’s Kim Jong-un.
Facebook Live: It’s 2018, Can Big Pharma Hold The Line Against Pricing Controls?
In this chat, KHN senior correspondent Jay Hancock discusses how drug-pricing battles could play out this year in D.C., state legislatures and beyond. What do we know about the drug industry’s agenda to quiet the drumbeat of cost control and transparency proposals? How will they officials target their efforts? Will the battles take place at the state level? Senior editor Stephanie Stapleton moderates.
HHS Nominee Vows To Tackle High Drug Costs, Despite His Ties To Industry
Alex M. Azar II, the former president of the U.S. division of Eli Lilly, says the U.S. drug system encourages price increases — but he intends to work on that problem.
Vuelve del retiro para ayudar a luchar contra la hepatitis C
Cuando se lanzó una prometedora droga para curar la enfermedad contra la que había luchado como médico por décadas, el doctor Robert Cirillo no dudó en volver a ejercer.
From Retirement To The Front Lines Of Hepatitis C Treatment
This doctor came out of retirement with the goal of treating every patient at high risk for hepatitis C he encounters. The problem is finding them.
Readers Have Bones To Pick, From Health System Flaws To Covering Pot Beat
Kaiser Health News gives readers a chance to comment on a recent batch of stories.
FDA Chief Says He’s Open To Rethinking Incentives On Orphan Drugs
The FDA’s Scott Gottlieb says the agency is focused on the big picture, and he wants to know why pharma churns out drugs for some rare diseases but not for others.
Arthritis Drugs Show How U.S. Drug Prices Defy Economics
Drugs that treat rheumatoid arthritis started out costing about $10,000 a year. Ten years later, they list for more than $40,000.
Biosimilars, Biologics And New Legal Challenges For RA Treatments
As biosimilar products reach the market and rival more established RA treatments, the players are exploring legal challenges involving antitrust and anti-competitive behavior.
Drug Industry Spent Millions To Squelch Talk About High Drug Prices
Last year, the pharma industry’ biggest trade group raised millions to change the conversation about drug pricing.
Experts Tell Congress How To Cut Drug Prices. We Give You Some Odds.
Some of the nation’s most influential scientists recommend eight steps to lower drug prices. KHN takes the political temperature and tells you the chances of Congress acting on them.
Cities, Counties and Schools Sidestep FDA Canadian Drug Crackdown, Saving Millions
Medicines are up to 80 percent cheaper north of the border and overseas, so U.S. localities are greasing a pharmaceutical pipeline that the feds warn is illegal and possibly unsafe.
Pace Of U.S. Health Spending Slows In 2016
Dramatic increases in spending that came with the influx of newly insured consumers in 2014 and 2015 appear to be moderating.
Podcast: ‘What The Health?’ Taxes, Medicare And The Year-End Mess
In this episode of “What the Health?” Julie Rovner of Kaiser Health News, Joanne Kenen of Politico and Paige Winfield Cunningham of The Washington Post discuss the possible impact of the tax bill on the Medicare program, confirmation hearings for a new secretary of Health and Human Services and the future of the Children’s Health Insurance Program. Plus, for “extra credit,” the panelists recommend their favorite health stories of the week.
The Ratcheting Price Of The Pneumococcal Vaccine: What Gives?
The price for Pfizer’s Prevnar 13 has increased 5 to 6 percent each year since its 2010 approval by the Food and Drug Administration.
Heated And Deep-Pocketed Battle Erupts Over 340B Drug Discount Program
Drugmakers, hospitals and lawmakers are taking sides in a showdown over a discount program that covers drug purchases at some hospitals.
